Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simonetta Buglioni

Showing results (41-50 of 88) with videos related to

Pageof 9
Sort By:
Oncotarget|February 13, 2016
Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cellsMarta Di Martile, Marianna Desideri, Teresa De Luca, et al.
Oncogenesis|March 14, 2021
USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancerFabiana Alejandra Rossi, Juliana Haydeé Enriqué Steinberg, Ezequiel Hernán Calvo Roitberg, et al.
Pathologica|August 31, 2021
Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS NetworkAntonio Marchetti, Mattia Barbareschi, Massimo Barberis, et al.
Clinical Lung Cancer|January 25, 2025
Kirsten Rat Sarcoma Virus Mutations Effect On Tumor Doubling Time And Prognosis Of Solid Dominant Stage I Lung AdenocarcinomaRiccardo Tajè, Vincenzo Ambrogi, Federico Tacconi, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophagesMarta Di Martile, Valentina Farini, Francesca Maria Consonni, et al.
Oncogenesis|February 16, 2020
microRNA-378a-5p iS a novel positive regulator of melanoma progressionMaria Grazia Tupone, Simona D'Aguanno, Marta Di Martile, et al.
Pathologica|September 18, 2025
Part III - Post-analytical phaseSimonetta Buglioni, Davide Seminati, Rossella Bruno, et al.
Cancers|June 24, 2022
A Real-World Systematic Analysis of Driver Mutations' Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant SettingIrene Terrenato, Cristiana Ercolani, Anna Di Benedetto, et al.
Oncology and Therapy|November 28, 2024
A Cross-Sectional Study of Variant Interpretation and Reporting of NGS Data Using Tertiary Analysis Software: Navify<sup>®</sup> Mutation ProfilerFrancesco Pepe, Gianluca Russo, Nadia Barraco, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2025
TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinomaFilippo Tommaso Gallina, Daniele Marinelli, Riccardo Tajè, et al.
Pageof 9

Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
Oncotarget|February 13, 2016
Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cellsMarta Di Martile, Marianna Desideri, Teresa De Luca, et al.
Oncogenesis|March 14, 2021
USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancerFabiana Alejandra Rossi, Juliana Haydeé Enriqué Steinberg, Ezequiel Hernán Calvo Roitberg, et al.
Pathologica|August 31, 2021
Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS NetworkAntonio Marchetti, Mattia Barbareschi, Massimo Barberis, et al.
Clinical Lung Cancer|January 25, 2025
Kirsten Rat Sarcoma Virus Mutations Effect On Tumor Doubling Time And Prognosis Of Solid Dominant Stage I Lung AdenocarcinomaRiccardo Tajè, Vincenzo Ambrogi, Federico Tacconi, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophagesMarta Di Martile, Valentina Farini, Francesca Maria Consonni, et al.
Oncogenesis|February 16, 2020
microRNA-378a-5p iS a novel positive regulator of melanoma progressionMaria Grazia Tupone, Simona D'Aguanno, Marta Di Martile, et al.
Pathologica|September 18, 2025
Part III - Post-analytical phaseSimonetta Buglioni, Davide Seminati, Rossella Bruno, et al.
Cancers|June 24, 2022
A Real-World Systematic Analysis of Driver Mutations' Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant SettingIrene Terrenato, Cristiana Ercolani, Anna Di Benedetto, et al.
Oncology and Therapy|November 28, 2024
A Cross-Sectional Study of Variant Interpretation and Reporting of NGS Data Using Tertiary Analysis Software: Navify<sup>®</sup> Mutation ProfilerFrancesco Pepe, Gianluca Russo, Nadia Barraco, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2025
TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinomaFilippo Tommaso Gallina, Daniele Marinelli, Riccardo Tajè, et al.
Pageof 9